Hybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program

dc.contributor.authorChevaisrakul P.
dc.contributor.authorLumjiaktase P.
dc.contributor.authorKietdumrongwong P.
dc.contributor.authorChuatrisorn I.
dc.contributor.authorChatsangjaroen P.
dc.contributor.authorPhanuphak N.
dc.contributor.otherMahidol University
dc.date.accessioned2023-05-19T07:51:14Z
dc.date.available2023-05-19T07:51:14Z
dc.date.issued2023-12-01
dc.description.abstractThe death rate from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in 2022 was lower than the death rate in 2021, when the infection rate increased. Hybrid immunity provided by a combination of vaccination and infection, including asymptomatic infection, may confer effective protection against death. We explored the combined effect of asymptomatic infection and hybrid immunity by studying T-cell and antibody responses against SARS-CoV-2 among individuals treated in home health care services 6 months after SARS-CoV-2 exposure. Asymptomatic SARS-CoV-2 infection was demonstrated in 24.4% of close contacts. The levels of immunity were not different between patients and close contacts. Anti-RBD IgG against SARS-CoV-2 increased in a dose-dependent manner with the number of vaccine doses. Interestingly, the T-cell response decreased soon after a booster dose of vaccine. Asymptomatic SARS-CoV-2 infection could not enhance immunity against SARS-CoV-2 among vaccinated close contacts. Full vaccination was crucial to provide hybrid immunity. However, when designing vaccine strategies, T-cell exhaustion after multiple vaccinations should be considered.
dc.identifier.citationScientific Reports Vol.13 No.1 (2023)
dc.identifier.doi10.1038/s41598-023-28101-5
dc.identifier.eissn20452322
dc.identifier.pmid36641523
dc.identifier.scopus2-s2.0-85146281691
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/82127
dc.rights.holderSCOPUS
dc.subjectMultidisciplinary
dc.titleHybrid and herd immunity 6 months after SARS-CoV-2 exposure among individuals from a community treatment program
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85146281691&origin=inward
oaire.citation.issue1
oaire.citation.titleScientific Reports
oaire.citation.volume13
oairecerif.author.affiliationRamathibodi Hospital
oairecerif.author.affiliationBDMS Health Research Center
oairecerif.author.affiliationInstitute of HIV Research and Innovation
oairecerif.author.affiliationNational Healthcare Systems Company Limited

Files

Collections